Loading...
Market
Will Pfizer's gene therapy for Hemophilia A receive FDA approval by December 31, 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Pfizer's $PFE Gene Therapy Shows Positive Results in Hemophilia A Late-Stage Phase 3 Study
Jul 24, 2024, 10:49 AM
Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The therapy, developed in collaboration with Sangamo Therapeutics, aims to reduce bleeding episodes in patients with the severe bleeding disorder. The study's success marks a significant milestone in the treatment of Hemophilia A, offering hope for improved management of the condition. Pfizer's stock symbol is $PFE, and the therapy met its goal in a pivotal late-stage trial.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0% to 10% • 25%
No significant change • 25%
Decrease • 25%